These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8997168)

  • 1. Effects of intravenous immune globulin on the peripheral lymphocyte phenotypes in Kawasaki disease.
    Lee HK; Kim DS; Noh GW; Lee KY
    Yonsei Med J; 1996 Oct; 37(5):357-63. PubMed ID: 8997168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.
    Ye Q; Gong FQ; Shang SQ; Hu J
    Clin Immunol; 2016 Oct; 171():25-31. PubMed ID: 27519954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of intravenous immunoglobulin on lymphocyte populations in children with Kawasaki syndrome.
    Saulsbury FT
    Clin Exp Rheumatol; 1992; 10(6):617-20. PubMed ID: 1483316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravenous immunoglobulin on inhibiting peripheral blood lymphocyte apoptosis in acute Kawasaki disease.
    Yi QJ; Li CR; Yang XQ
    Acta Paediatr; 2001 Jun; 90(6):623-7. PubMed ID: 11440093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between T-cell HLA-DR expression and intravenous immunoglobulin treatment response in Kawasaki disease.
    Wakiguchi H; Hasegawa S; Suzuki Y; Kudo K; Ichiyama T
    Pediatr Res; 2015 Apr; 77(4):536-40. PubMed ID: 25580740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
    Ichiyama T; Ueno Y; Hasegawa M; Ishikawa Y; Matsubara T; Furukawa S
    Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease.
    Guo MM; Tseng WN; Ko CH; Pan HM; Hsieh KS; Kuo HC
    Allergy; 2015 Mar; 70(3):310-8. PubMed ID: 25585854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of immunocyte activation during intravenous immunoglobulin treatment in Kawasaki disease.
    Matsuguma C; Wakiguchi H; Suzuki Y; Okada S; Furuta T; Ohnishi Y; Azuma Y; Ohga S; Hasegawa S
    Scand J Rheumatol; 2019 Nov; 48(6):491-496. PubMed ID: 31272272
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
    Tsujimoto H; Takeshita S; Nakatani K; Kawamura Y; Tokutomi T; Sekine I
    Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. scRNA+TCR-seq reveals the pivotal role of dual receptor T lymphocytes in the pathogenesis of Kawasaki disease and during IVIG treatment.
    Xu Y; Yuan Y; Mou L; Hui L; Zhang X; Yao X; Li J
    Front Immunol; 2024; 15():1457687. PubMed ID: 39421738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased CD5+ B cells during the acute phase of Kawasaki disease.
    Kim HS; Noh GW; Kim DS; Lee KY; Lee HS; Lee HK; Lee SI
    Yonsei Med J; 1996 Feb; 37(1):52-8. PubMed ID: 8967110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy.
    Leucht S; Uttenreuther-Fischer MM; Gaedicke G; Fischer P
    Clin Immunol; 2001 Apr; 99(1):18-29. PubMed ID: 11286538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in CD69, CD25 and HLA-DR expressions in peripheral blood T cells in Kawasaki disease].
    Zhang YY; Huang XM; Kang ML; Gong FQ; Qian BQ
    Zhonghua Er Ke Za Zhi; 2006 May; 44(5):329-32. PubMed ID: 16780706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin.
    Leung DY; Burns JC; Newburger JW; Geha RS
    J Clin Invest; 1987 Feb; 79(2):468-72. PubMed ID: 2433307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunologic effects of IVIG in Kawasaki disease.
    Leung DY
    Int Rev Immunol; 1989; 5(2):197-202. PubMed ID: 8691053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome.
    Klassen TP; Rowe PC; Gafni A
    J Pediatr; 1993 Apr; 122(4):538-42. PubMed ID: 8463897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoregulatory changes in Kawasaki disease.
    Jason J; Gregg L; Han A; Hu A; Inge KL; Eick A; Tham I; Campbell R
    Clin Immunol Immunopathol; 1997 Sep; 84(3):296-306. PubMed ID: 9281389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of Th17 cells and the related cytokines with treatment in Kawasaki disease.
    Rasouli M; Heidari B; Kalani M
    Immunol Lett; 2014 Nov; 162(1 Pt A):269-75. PubMed ID: 25277751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.